In this study, we evaluated the Sel-Cap lung cancer panel, an NGS-based genotyping platform for the detection of EGFR mutations in patients with NSCLC, and we focused specifically on its diagnostic performance while serving as a liquid biopsy platform. This evidence concerns the gene EGFR and lung carcinoma.